Companies in #Fibrosis

Enveda is an AI-driven drug discovery company that reads nature's untapped chemistry through metabolomics and machine learning to discover small-molecule medicines roughly four times faster than the industry average. Its pipeline spans obesity and metabolic disease, immunology and inflammation, fibrosis and neurosensory disorders, and the company has raised more than $845 million since 2019.

Insilico Medicine is an end-to-end generative artificial intelligence-driven drug discovery company connecting biology, chemistry, and clinical trials analysis.

PureTech Health is a clinical-stage biotherapeutics company developing innovative medicines for serious diseases. It founded and spun out multiple companies including Karuna, Gelesis, and Celea, with a current focus on lymphatic and CNS-targeted therapeutics.

Redx Pharma is a clinical-stage biopharmaceutical company developing precision medicines targeting oncology and fibrotic diseases, with a pipeline of small molecule inhibitors of oncogenic and fibrotic pathways.

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead product, apitegromab, is being developed for spinal muscular atrophy (SMA).

Clinical-stage biopharmaceutical company developing peripheral CB1 receptor therapies for obesity and metabolic conditions. Recently combined with Redx Pharma into Fibrx Therapeutics to advance a fibrosis-focused pipeline.